EC Number   |
Application |
Reference |
|---|
    1.13.11.52 | drug development |
increased levels of hIDO1 expression in tumor cells correlate with a poor prognosis for surviving several cancer types. hIDO1 is a drug target for cancer therapy, design of de novo inhibitors selective for hIDO1. |
742005 |
| 1.13.11.52 | drug development |
the enzyme is a promising therapeutic target of cancer |
724912 |
| 1.13.11.52 | drug development |
the enzyme is a target for drug development |
743064 |
| 1.13.11.52 | drug development |
therapeutic inhibition of IDO1 is receiving much attention due to its proposed role in the pathogenesis of several diseases including cancer, hypotension and neurodegenerative disorders |
724429 |
| 1.13.11.52 | medicine |
engraftment of IDO expressing skin substitutes on the back of rats significantly improves healing progression over 7 days compared with both nontreated and non-IDO-expressing skin substitutes |
713591 |
| 1.13.11.52 | medicine |
enzyme catalyzes the first and rate-limiting step in kynurenine pathway |
659233 |
| 1.13.11.52 | medicine |
expression of indoleamine 2,3-dioxygenase may be deleterious during renal inflammation, because it enhances TEC self-injury through Fas/FasL interactions. Attenuation of indoleamine 2,3-dioxygenase may represent a novel strategy to promote kidney function following ischemia and renal allograft rejection |
684370 |
| 1.13.11.52 | medicine |
first and probably rate-limiting enzyme in UV filter biosynthesis |
395469 |
| 1.13.11.52 | medicine |
first and rate-limiting enzyme in tryptophan metabolism, plays a role in pathogenesis of many diseases |
395463, 660438 |
| 1.13.11.52 | medicine |
genetic alteration of fetal IDO gene is not a primary cause of pre-eclampsia |
710824 |
